Generex Biotechnology Partner Olaregen Therapeutix
Post# of 36566
(Total Views: 408)
Posted On: 03/26/2019 9:15:32 AM
Generex Biotechnology Partner Olaregen Therapeutix, Inc. Selected to Present a Formal Poster Session at Prestigious Diabetic Limb Salvage Meeting
9:00 AM ET, 03/26/2019 - GlobeNewswire
Excellagen Clinical Trial Analysis: Rapid Healing of Diabetic Neuropathic Foot Ulcers
Presentation on Friday Evening April 5, 2019 at the JW Marriott Hotel in Washington, DC
MIRAMAR, FL, March 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Generex Biotechnology Corporation (OTCMKTS: GNBT) today announced that its subsidiary, Olaregen Therapeutix, Inc., has been selected to present clinical data and a subset analysis of the Excellagen clinical trial dataset in a formal poster presentation. Dr. Lois Chandler, inventor of Excellagen and an advisor to Olaregen, will be presenting the poster, Wound Conforming Matrix (WCM) Promotes Rapid Healing of Diabetic Neuropathic Foot Ulcers: Subset Analysis of Randomized Controlled Trial on Friday evening, April 5th in a special poster session at the JW Marriott Hotel in Washington DC, the official site of the DLS Meeting. The poster will present clinical data demonstrating acceleration in wound healing for Olaregen’s Excellagen (formulated fibrillar collagen 2.6%) as compared with Standard of Care (SOC) in patients with diabetic neuropathic foot ulcers.
Dr. Chandler’s co-authors on the manuscript include Robert Kirsner, MD, PhD (University of Miami), Oscar Alvarez, PhD (Rutgers University), Peter Blume, DPM, (Yale University), John Lantis, MD (Mount Sinai Hospital – NY), Paul Kim, DPM (Georgetown University), and William Marston, MD (University of North Carolina).
The Diabetic Limb Salvage meeting will be attended by approximately 500 wound care clinicians and researchers from around the world dedicated to treating diabetes-related foot complications, including diabetic foot ulcers (DFUs), which are leading causes of non-traumatic lower extremity amputation. In the United States, a total of $176 billion is spent annually on direct costs for diabetes, and as much as one third of that (>$50 billion) is spent on lower extremity complications (Driver et al, J Vasc Surg 2010).
Olaregen Therapeutix is preparing for the impending launch of Excellagen, an FDA 510K cleared device for a broad array of dermal wounds, including diabetic foot ulcers. “This is a very exciting opportunity for Olaregen to have our clinical research on Excellagen selected for presentation at one of the most preeminent wound care events in the world, providing us with a highly visible platform to highlight the benefits of Excellagen for the treatment of diabetic foot ulcers,” said Anthony Dolisi, CEO & President of Olaregen. “As we are introducing Excellagen to the market next month, the DLS meeting serves as an invaluable launching pad to reach the experts in diabetes care.”
Joe Moscato, CEO of Generex, commented, "We are excited at Generex to have our subsidiary Olaregen launch Generex’ first U.S. commercial product, Excellagen wound conforming matrix that is FDA-cleared for 17 wound healing indications, including diabetic foot ulcers. The performance of the Olaregen management team in launching Excellagen demonstrates our strategy to acquire great companies with innovative, FDA approved products, guided by exceptional management teams that can execute on strategic and commercial plans. We wish Dr. Chandler the best in her poster presentation.”
9:00 AM ET, 03/26/2019 - GlobeNewswire
Excellagen Clinical Trial Analysis: Rapid Healing of Diabetic Neuropathic Foot Ulcers
Presentation on Friday Evening April 5, 2019 at the JW Marriott Hotel in Washington, DC
MIRAMAR, FL, March 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Generex Biotechnology Corporation (OTCMKTS: GNBT) today announced that its subsidiary, Olaregen Therapeutix, Inc., has been selected to present clinical data and a subset analysis of the Excellagen clinical trial dataset in a formal poster presentation. Dr. Lois Chandler, inventor of Excellagen and an advisor to Olaregen, will be presenting the poster, Wound Conforming Matrix (WCM) Promotes Rapid Healing of Diabetic Neuropathic Foot Ulcers: Subset Analysis of Randomized Controlled Trial on Friday evening, April 5th in a special poster session at the JW Marriott Hotel in Washington DC, the official site of the DLS Meeting. The poster will present clinical data demonstrating acceleration in wound healing for Olaregen’s Excellagen (formulated fibrillar collagen 2.6%) as compared with Standard of Care (SOC) in patients with diabetic neuropathic foot ulcers.
Dr. Chandler’s co-authors on the manuscript include Robert Kirsner, MD, PhD (University of Miami), Oscar Alvarez, PhD (Rutgers University), Peter Blume, DPM, (Yale University), John Lantis, MD (Mount Sinai Hospital – NY), Paul Kim, DPM (Georgetown University), and William Marston, MD (University of North Carolina).
The Diabetic Limb Salvage meeting will be attended by approximately 500 wound care clinicians and researchers from around the world dedicated to treating diabetes-related foot complications, including diabetic foot ulcers (DFUs), which are leading causes of non-traumatic lower extremity amputation. In the United States, a total of $176 billion is spent annually on direct costs for diabetes, and as much as one third of that (>$50 billion) is spent on lower extremity complications (Driver et al, J Vasc Surg 2010).
Olaregen Therapeutix is preparing for the impending launch of Excellagen, an FDA 510K cleared device for a broad array of dermal wounds, including diabetic foot ulcers. “This is a very exciting opportunity for Olaregen to have our clinical research on Excellagen selected for presentation at one of the most preeminent wound care events in the world, providing us with a highly visible platform to highlight the benefits of Excellagen for the treatment of diabetic foot ulcers,” said Anthony Dolisi, CEO & President of Olaregen. “As we are introducing Excellagen to the market next month, the DLS meeting serves as an invaluable launching pad to reach the experts in diabetes care.”
Joe Moscato, CEO of Generex, commented, "We are excited at Generex to have our subsidiary Olaregen launch Generex’ first U.S. commercial product, Excellagen wound conforming matrix that is FDA-cleared for 17 wound healing indications, including diabetic foot ulcers. The performance of the Olaregen management team in launching Excellagen demonstrates our strategy to acquire great companies with innovative, FDA approved products, guided by exceptional management teams that can execute on strategic and commercial plans. We wish Dr. Chandler the best in her poster presentation.”
(1)
(0)